Loncar Cancer Immunotherapy Index Conducts Semi-Annual Rebalance
December 21 2016 - 8:30AM
Business Wire
Two Biotechnology Companies Added to the
Index
Loncar Investments, LLC today announced the result of the
semi-annual rebalance and reconstitution of the Loncar Cancer
Immunotherapy Index, a group of the top 30 companies developing
cancer immunotherapy treatments and discovering new ways to use the
body’s immune system to fight cancer.
As the cancer immunotherapy space continues to evolve,
research-centric biotechnology companies that specialize in
immunotherapy are more numerous, innovative, and have a larger role
to play in the field’s growth. Therefore, the committee that
governs the index has chosen to increase this group’s weighting.
The index will now combine 25 small-to mid-cap biotechnology
companies (up from 23) and five large cap companies (down from
seven).
The Committee has added Curis (Nasdaq: CRIS) and Sorrento
Therapeutics (Nasdaq: SRNE) to the index.
These additions replace Celgene (Nasdaq: CELG) and Pfizer (NYSE:
PFE).
“It has been inspiring to watch the first generation of
immunotherapies reach the market and make a difference for a
growing number of patients,” said Brad Loncar, Chairman of the
index committee. “Innovative biotechnology companies hold the key
to building on that success via new immunotherapy approaches and we
are happy to add two such companies to the index today.”
Effective this week, all index holdings have been rebalanced to
hold equal weight. The index is rebalanced and reconstituted
semi-annually. The next rebalance will occur on June 20, 2017.
Loncar Investments is an official partner of the Cancer Research
Institute, the world’s only nonprofit organization dedicated
exclusively to harnessing the immune system’s power to conquer all
cancers. To learn about how to give to CRI, please visit here.
Why immunotherapy: Cancer immunotherapy has become an
important sector in the biotechnology space and is changing the way
many cancers are treated. While traditional medicines like
chemotherapies often give cancer a broad punch, the benefit of
using immunotherapy is derived from the immune system's dynamic
nature and the way it can more precisely be tailored to fight a
patient's disease. Some immunotherapies have already exhibited
uncommon results in clinical trials including partial and complete
responses in late stage cancer patients.
About the index: The Loncar Cancer Immunotherapy Index is
an equal-weighted index of 30 top immunotherapy companies
rebalanced and reconstituted on a semi-annual basis. Price and
return data are independently calculated on a daily basis by Indxx,
LLC. This is a sector index similar to Technology sector indices
(Internet, Cyber Security, Cloud Computing, etc.). Sector indices
allow investors to track interest areas more precisely than broad
indices. Additional information can be found at the index’s
dedicated website, www.LoncarIndex.com.
Index provider: Loncar Investments, LLC is committed to
making the biotechnology space more approachable to a wider range
of investors. The company is principally owned by biotech investor
and analyst Brad Loncar. Mr. Loncar manages a biotech-focused
family portfolio from his Lenexa, Kan. office. He can be followed
on Twitter at @bradloncar and his commentary is available at
www.loncarblog.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161221005085/en/
for Nasdaq ETF VenturesLeah Katsanis,
610-228-2117ise@gregoryfca.com
Curis (NASDAQ:CRIS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Curis (NASDAQ:CRIS)
Historical Stock Chart
From Apr 2023 to Apr 2024